Drug Profile
V 10367
Alternative Names: VA 10367Latest Information Update: 09 Feb 2004
Price :
$50
*
At a glance
- Originator Vertex Pharmaceuticals
- Class Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Neurological disorders; Parkinson's disease
Most Recent Events
- 22 Nov 2003 Discontinued - Preclinical for Neurological disorders in USA (PO)
- 22 Nov 2003 Discontinued - Preclinical for Parkinson's disease in USA (unspecified route)
- 22 Nov 2001 No-Development-Reported for Neurological disorders in USA (PO)